Bak­er Bros. places a $250M bet on a po­ten­tial ri­val to Re­gen­eron and No­var­tis — with a $1B-plus pay­off on the line

Ko­di­ak Sci­ences dis­ap­point­ed plen­ty of in­vestors when it priced its IPO shares $KOD at $10 a pop, well be­low the range, last fall. But shares have al­most tripled in the mean­time, push­ing its mar­ket cap to $1.1 bil­lion — and set­ting the stage for a $250 mil­lion raise from Bak­er Bros. to fund a piv­otal pro­gram for their Eylea ri­val.

Biotech-fo­cused Bak­er Bros. Ad­vi­sors stepped up bear­ing $225 mil­lion to nail a 4.5% roy­al­ty stream on KS-301, the big drug at Ko­di­ak. The biotech launched their first piv­otal tri­al — DAZ­ZLE — a cou­ple of months ago. They get $100 mil­lion of Bak­er cash in Jan­u­ary, with the rest trig­gered on a slate of mile­stones that in­cludes 50% en­roll­ment in the late-stage ef­fort.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Recon Strategy

Boston, MA, USA